Oddo BHF Asset Management Sas Makes New $35.05 Million Investment in Boston Scientific Co. (NYSE:BSX)

Oddo BHF Asset Management Sas bought a new position in Boston Scientific Co. (NYSE:BSX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 418,213 shares of the medical equipment provider's stock, valued at approximately $35,046,000. Boston Scientific comprises approximately 1.7% of Oddo BHF Asset Management Sas' holdings, making the stock its 8th largest holding.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Dunhill Financial LLC raised its position in Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after buying an additional 152 shares during the last quarter. Triad Wealth Partners LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $26,000. Values First Advisors Inc. bought a new position in Boston Scientific during the third quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. purchased a new stake in Boston Scientific in the third quarter worth approximately $30,000. Finally, Capital Performance Advisors LLP bought a new stake in Boston Scientific in the 3rd quarter worth approximately $30,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

Shares of BSX stock traded down $0.31 during trading hours on Friday, hitting $90.12. The stock had a trading volume of 3,181,501 shares, compared to its average volume of 5,970,553. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock has a market capitalization of $132.81 billion, a price-to-earnings ratio of 74.73, a PEG ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a one year low of $54.95 and a one year high of $91.93. The stock's 50-day moving average price is $87.87 and its two-hundred day moving average price is $81.67.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company posted $0.50 EPS. The company's revenue was up 19.3% compared to the same quarter last year. Equities analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares in the company, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 328,157 shares of company stock worth $27,957,676. Insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Barclays raised their price target on Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a research note on Thursday, August 22nd. Royal Bank of Canada boosted their price target on Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Morgan Stanley increased their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, October 24th. BTIG Research boosted their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, Mizuho increased their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $94.43.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.